|Bioscientist Royston turns his attention to creating a center in San Diego's crowded research community|
Ivor Royston, who at the age of 33 founded Hybritech Inc., the first company in the United States to exploit monoclonal antibodies commercially, and who became a millionaire in the process, is taking his vision for enterprise to a new nonprofit venture.
Among the palm trees, a handful of research institutes, and the 90 biotechnology companies that make San Diego an idyllic place for scientists to work, Royston is opening a clinical research cancer center.
The entrepreneur hopes his small cancer center, with its initial focus on immunotherapy and gene therapy research and clinical care, will flower into a full-fledged research and cancer care facility and be a resource for cancer researchers and oncologists of the 21st century.
|Since 1971, when Congress passed the National Cancer Act, legislators and scientists have attempted to address the...|
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?